Cadonilimab Combined With Liposomal Irinotecan Plus Leucovorin and Fluorouracil for Advanced Cholangiocarcinoma
A phase 2 trial of cadonilimab, fluorouracil, leucovorin and liposomal irinotecan in gallbladder cancer and other biliary tract cancers, run by West China Hospital, now recruiting.
Overview
Cadonilimab Combined With Liposomal Irinotecan Plus Leucovorin and Fluorouracil for Advanced Cholangiocarcinoma is a phase 2 interventional study registered as NCT06438822 by West China Hospital, with a registry enrolment figure of 51 participants, started 2024-08-30 and due to reach its primary completion in 2026-08-30. Interventions recorded: Cadonilimab Combined With Liposomal Irinotecan Plus Leucovorin and Fluorouracil. Conditions listed: Cholangiocarcinoma. Gallbladder cancer is named in the registry entry: "1. Diagnosed with pathologically confirmed locally advanced unresectable or metastatic adenocarcinoma of the bile ducts, gallbladder, or cholangiocellular carcinoma, with primary tumors located in the intrahepatic bile d". Sites: China. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialLiposomal Irinotecan Plus 5-FU/LV and Sintilimab With Sequential SBRT for Locally Advanced Biliary Tract Cancer
Shares Liposomal irinotecan, Leucovorin (folinic acid), Extrahepatic cholangiocarcinoma (perihilar and distal), Intrahepatic cholangiocarcinoma and the tag gallbladder-deep-dive.
- TrialLigufalimab and Cadonilimab in Advanced Liver Cancers
Shares Cadonilimab, Extrahepatic cholangiocarcinoma (perihilar and distal), Intrahepatic cholangiocarcinoma, Bispecific antibodies and the tag gallbladder-deep-dive.
- TrialNAPOLI-2: Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Biliary Cancer
Shares Liposomal irinotecan, Leucovorin (folinic acid), Fluorouracil (5-FU), Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups) and the tag gallbladder-deep-dive.
- TrialA Randomized, Two-cohort, Prospective Phase II Clinical Study of the Second-line Treatment of Advanced Biliary System Tumors With Liposomal Irinotecan (II) Combination Regimen
Shares Liposomal irinotecan, Extrahepatic cholangiocarcinoma (perihilar and distal), Intrahepatic cholangiocarcinoma, Fluorouracil (5-FU) and the tag gallbladder-deep-dive.
- TrialIvonescimab in Combination With Liposomal Irinotecan and 5-FU/LV in Potentially Resectable Biliary Tract Malignancies
Shares Liposomal irinotecan, Fluorouracil (5-FU), Bispecific antibodies, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups) and the tag gallbladder-deep-dive.
- TrialSintilimab Plus NALIRIFOX or Gemcitabine-Cisplatin as First-Line Treatment for Metastatic Biliary Tract Cancer
Shares Leucovorin (folinic acid), Extrahepatic cholangiocarcinoma (perihilar and distal), Intrahepatic cholangiocarcinoma, Fluorouracil (5-FU) and the tag gallbladder-deep-dive.
- TrialSequential Anti-Angiogenic Therapy After Immunotherapy in Advanced Biliary Tract Cancer
Shares Leucovorin (folinic acid), Extrahepatic cholangiocarcinoma (perihilar and distal), Intrahepatic cholangiocarcinoma, Fluorouracil (5-FU) and the tag gallbladder-deep-dive.
- TrialDurvalumab Combined With S-1 as Adjuvant Therapy of Resectable BTC
Shares Extrahepatic cholangiocarcinoma (perihilar and distal), Intrahepatic cholangiocarcinoma, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (cholangiocarcinoma) and the tag gallbladder-deep-dive.